TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:01
Candel Therapeutics Inc. ( CADL ) https://www.candeltx.com
9.17USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
CADL
559.71%
SPY
32.66%
CADL
23.09%
SPY
108.59%
CADL
0.00%
SPY
302.52%
CADL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
281.72
279.79
2.09
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.40
77.95
-18.46
-13.66
0.00
-8.48
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-482.60
-14.02
-464.48
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-61.67
-68.60
0.00
Other Earnings and Cash Flow Stats:
Candel Therapeutics Inc. ( CADL ) Net Income TTM ($MM) is -52.20
Candel Therapeutics Inc. ( CADL ) Operating Income TTM ($MM) is -35.55
Candel Therapeutics Inc. ( CADL ) Owners' Earnings Annual ($MM) is 0.00
Candel Therapeutics Inc. ( CADL ) Current Price to Owners' Earnings ratio is 0.00
Candel Therapeutics Inc. ( CADL ) EBITDA TTM ($MM) is -34.55
Candel Therapeutics Inc. ( CADL ) EBITDA Margin is -464.48%
Capital Allocation:
Candel Therapeutics Inc. ( CADL ) has paid 0.00 dividends per share and bought back -3.093759 million shares in the past 12 months
Candel Therapeutics Inc. ( CADL ) has reduced its debt by 7.918 million USD in the last 12 months
Capital Structure:
Candel Therapeutics Inc. ( CADL ) Interest-bearing Debt ($MM) as of last quarter is 14
Candel Therapeutics Inc. ( CADL ) Annual Working Capital Investments ($MM) are -4
Candel Therapeutics Inc. ( CADL ) Book Value ($MM) as of last quarter is -16
Candel Therapeutics Inc. ( CADL ) Debt/Capital as of last quarter is -96%
Other Balance Sheet Stats:
Candel Therapeutics Inc. ( CADL ) has 16 million in cash on hand as of last quarter
Candel Therapeutics Inc. ( CADL ) has 15 million of liabilities due within 12 months, and long term debt 14 as of last quarter
Candel Therapeutics Inc. ( CADL ) has 32 common shares outstanding as of last quarter
Candel Therapeutics Inc. ( CADL ) has 0 million USD of preferred stock value
Academic Scores:
Candel Therapeutics Inc. ( CADL ) Altman Z-Score is -11.72 as of last quarter
Candel Therapeutics Inc. ( CADL ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Candel Therapeutics Inc. ( CADL ) largest shareholder is Tower Research Capital LLC owning 8647 shares at 0.08 ($MM) value
Manning Paul B(an insider) Bought 750000 shares of Candel Therapeutics Inc. ( CADL ) for the amount of $4500000.00 on 2024-12-16
30.39% of Candel Therapeutics Inc. ( CADL ) is held by insiders, and 22.53% is held by institutions
Candel Therapeutics Inc. ( CADL ) went public on 2021-07-27
Other Candel Therapeutics Inc. ( CADL ) financial metrics:
FCF:-28.70
Unlevered Free Cash Flow:0.00
EPS:-1.33
Operating Margin:-482.60
Gross Profit Margin:-14.02
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:279.11
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Candel Therapeutics Inc. ( CADL ) :
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops theenLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.